Our approach offers broad applications across both approved and emerging CAR T therapies, with the potential to extend its reach across diverse patient populations, therapeutic platforms, and clinical indications.
Our products are engineered for seamless integration with existing GMP-compliant manufacturing frameworks, presenting manufacturers a scalable and cost-efficient solution with minimal protocol modifications.
Empowering Cancer Care with Advanced Cell Therapy
Our mission is to develop transformative cell therapies for cancer cure through navigating therapeutic immune cells​​​
Problem Statement
CAR T therapy has revolutionized the treatment of blood cancers, but has been faced with challenges such as primary resistance and losing the ability to target and attack the cancer. Current strategies aim at enhancing the curative potential of CAR T therapy, which are deemed inadequate to address the multifactorial nature of treatment failure.
Cutting-Edge Universal Solutions
Our inventions focus on improving the initial events during CAR T therapy, thus seizing a completely new therapeutic angle to augment bone marrow homing, enable early tumor clearance and prevent overt relapses that are unique attributes distinctive from what have been built in the field.
Competitive Edge
In addition, this novel approach of navigating CAR T cells to the bone marrow compartment is expected to be widely applicable to any blood cancers, thereby putting forward a universal solution to succeed the currently approved CAR modalities without target/disease restriction.
Any cell.
​
Any site.
​
Any cancer.
Our Collaborative Network
